Synthaverse S.A. Total Liabilities

Latest as of March 2025: zł177.72 Million PLN ≈ $48.91 Million USD

Synthaverse S.A. total liabilities. Based on the latest financial reports, Synthaverse S.A. (SVE) has total liabilities worth zł177.72 Million PLN (≈ $48.91 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Synthaverse S.A.'s assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Synthaverse S.A. (2010–2024)

Total liabilities of Synthaverse S.A. from 2010 to 2024. This chart illustrates how Synthaverse S.A.'s total liabilities have evolved over time, based on quarterly financial data.

Synthaverse S.A. Competitors by Total Liabilities

The table below lists competitors of Synthaverse S.A. ranked by their total liabilities.

Company Country Total Liabilities
Saehwa IMC Co Ltd
KO:145210
Korea ₩73.32 Billion
Broad Capital Acquisition Corp
NASDAQ:BRAC
USA $13.30 Million
Xin Chio Global Co Ltd
TWO:3171
Taiwan NT$668.54 Million
Supremex Inc.
TO:SXP
Canada CA$197.87 Million
ADOLFO DOMINGUEZ
MC:ADZ
Spain €88.19 Million
An Gia Real Estate Investment and Development Corp
VN:AGG
Vietnam ₫1.88 Trillion
Reitmans (Canada) Limited
V:RET-A
Canada CA$277.05 Million
Hil Industries Bhd
KLSE:8443
Malaysia RM171.13 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Synthaverse S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Synthaverse S.A. (SVE) total assets.

Liquidity & Leverage Metrics

Synthaverse S.A. Total Liabilities Ratios Explained

Synthaverse S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.47 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.60 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Synthaverse S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Synthaverse S.A. (2010–2024)

The table below shows the annual total liabilities of Synthaverse S.A. from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 zł177.15 Million
≈ $48.75 Million
+15.59%
2023-12-31 zł153.26 Million
≈ $42.18 Million
+166.37%
2022-12-31 zł57.54 Million
≈ $15.84 Million
+36.11%
2021-12-31 zł42.27 Million
≈ $11.63 Million
-12.94%
2020-12-31 zł48.55 Million
≈ $13.36 Million
+0.65%
2019-12-31 zł48.24 Million
≈ $13.28 Million
-13.63%
2018-12-31 zł55.85 Million
≈ $15.37 Million
-11.65%
2017-12-31 zł63.22 Million
≈ $17.40 Million
-43.32%
2016-12-31 zł111.53 Million
≈ $30.69 Million
-23.69%
2015-12-31 zł146.16 Million
≈ $40.23 Million
+165.36%
2014-12-31 zł55.08 Million
≈ $15.16 Million
+40.44%
2013-12-31 zł39.22 Million
≈ $10.79 Million
-20.57%
2012-12-31 zł49.38 Million
≈ $13.59 Million
-12.13%
2011-12-31 zł56.19 Million
≈ $15.46 Million
-5.41%
2010-12-31 zł59.41 Million
≈ $16.35 Million
--

About Synthaverse S.A.

WAR:SVE Poland Biotechnology
Market Cap
$55.05 Million
zł200.03 Million PLN
Market Cap Rank
#21351 Global
#189 in Poland
Share Price
zł2.64
Change (1 day)
-0.38%
52-Week Range
zł2.64 - zł4.19
All Time High
zł30.00
About

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more